Compare FOXF & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FOXF | SLS |
|---|---|---|
| Founded | 2007 | 2012 |
| Country | United States | United States |
| Employees | 3700 | N/A |
| Industry | Motor Vehicles | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 782.9M | 924.5M |
| IPO Year | 2013 | 2007 |
| Metric | FOXF | SLS |
|---|---|---|
| Price | $18.78 | $8.06 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $30.25 | $10.00 |
| AVG Volume (30 Days) | 469.2K | ★ 8.5M |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.00 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,467,321,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.90 | $110.98 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 5.27 | N/A |
| 52 Week Low | $13.08 | $1.39 |
| 52 Week High | $31.18 | $9.51 |
| Indicator | FOXF | SLS |
|---|---|---|
| Relative Strength Index (RSI) | 58.43 | 55.54 |
| Support Level | $18.03 | $7.07 |
| Resistance Level | $19.09 | $9.51 |
| Average True Range (ATR) | 0.70 | 0.66 |
| MACD | 0.05 | -0.16 |
| Stochastic Oscillator | 84.09 | 45.84 |
Fox Factory Holding Corp is a designer, manufacturer, and marketer of performance-defining products and systems used predominantly on bikes, Side-by-Sides, on-road vehicles with and without off-road capabilities, off-road vehicles and trucks, ATVs, snowmobiles, specialty vehicles and applications, motorcycles, and commercial trucks. Its business operates under the FOX, FOX RACING SHOX, and RACE FACE brands. Geographically, it derives a majority of revenue from North America and also has a presence in Asia, Europe, and the Rest of the World. The company operates in three segments: Powered Vehicles Group, Aftermarket Applications Group, and Specialty Sports Group, of which it derives maximum revenue from Specialty Sports Group segment.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.